Survival Associations of Timely Postoperative Radiotherapy Among Head and Neck Cancer High-Risk Subgroups

被引:0
|
作者
Velez, Lisa M. Velez [1 ]
Corpuz, Timothy V. [1 ]
Schwetschenau, Luke C. [1 ]
Mazul, Angela [2 ]
Massa, Sean T. [1 ]
机构
[1] St Louis Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63103 USA
[2] Washington Univ, Sch Med St Louis, Dept Otolaryngol Head & Neck Surg, St Louis, MO USA
来源
LARYNGOSCOPE | 2025年
关键词
head and neck cancer; postoperative radiotherapy; survival; SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; TREATMENT DELAYS; SURGERY; DISPARITIES; INITIATION; IMPACT; RACE;
D O I
10.1002/lary.32074
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
ObjectiveEffective implementation of timely postoperative radiation therapy (PORT) as a quality metric for head and neck squamous cell carcinoma (HNSCC) care may reduce survival disparities in subgroups with the highest risk of mortality-advanced stage and Black race. We sought to determine if the association between timely PORT and survival varies among clinical and demographic high-risk subgroups.MethodsIn this retrospective cohort study using the National Cancer Database 2004-2020, patients with HPV-negative HNSCC treated with surgery and PORT were identified. The association between PORT delay greater than 6 weeks with overall survival was assessed by Cox proportional hazards models with interaction effects for race, overall stage, and PORT delay.ResultsAmong 54,035 patients included in the study, 62% (33491) had PORT delays. Black patients were more likely to have PORT delays (aOR 1.19, 95% CI: 1.10-1.27). Timely PORT was only associated with improved survival for all stage I patients and White stage IV patients (predicted mortality risk 2.53, 95% CI: 2.34-2.74 versus 2.88, 95% CI: 2.67-3.09, referenced to White, stage I). After adjusting for covariates, timely PORT was estimated to be associated with inferior overall survival in Black patients with stage IV disease although with low precision (predicted mortality risk 3.24, 95% CI: 2.87-3.66, versus 2.71, 95% CI: 2.47-2.98, referenced to White, stage I).ConclusionTimely, guideline-adherent PORT may not reduce survival disparities in Black patients, especially those with advanced stage disease, suggesting other interventions are needed to address this disparity.Level of Evidence3.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Delivery of Timely Adjuvant Radiation Among Veterans With Head and Neck Cancer
    Gulati, Jasmine
    Shah, Anuja
    Shah, Veranca
    Haupt, Thomas
    Walsh, Amanda
    Maxwell, Jessica H.
    OTO OPEN, 2025, 9 (01)
  • [32] Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis
    Dou, Shengjin
    Wang, Xin
    Xiao, Ying
    Zhang, Lin
    Jiang, Wen
    Ye, Lulu
    Wang, Yu
    He, Yining
    Liu, Shengwen
    Li, Rongrong
    Zhu, Guopei
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2025, 53
  • [33] Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis
    Christiane Matuschek
    Jan Haussmann
    Edwin Bölke
    Stephan Gripp
    Patrick J. Schuler
    Bálint Tamaskovics
    Peter Arne Gerber
    Freddy-Joel Djiepmo-Njanang
    Kai Kammers
    Christian Plettenberg
    Bahar Anooshahr
    Klaus Orth
    Wilfried Budach
    Radiation Oncology, 13
  • [34] Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer
    Kishan, Amar U.
    Duchesne, Gillian
    Wang, Pin-Chieh
    Rwigema, Jean-Claude M.
    Kishan, Arun U.
    Saigal, Christopher
    Rettig, Matthew
    Steinberg, Michael L.
    King, Christopher R.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (08): : 739 - 746
  • [35] MARGINAL MISSES AFTER POSTOPERATIVE INTENSITY-MODULATED RADIOTHERAPY FOR HEAD AND NECK CANCER
    Chen, Allen M.
    Farwell, D. Gregory
    Luu, Quang
    Chen, Leon M.
    Vijayakumar, Srinivasan
    Purdy, James A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (05): : 1423 - 1429
  • [36] Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients
    Rosenthal, Eben L.
    Chung, Thomas K.
    Carroll, William R.
    Clemons, Lisa
    Desmond, Renee
    Nabell, Lisle
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (13) : 4263 - 4269
  • [37] KNOWLEDGE OF HEAD AND NECK CANCER AND SMOKING BEHAVIOR IN A HIGH-RISK POPULATION IN INDONESIA
    Risbud, Adwight
    Amma, Asmaryadi
    Sultan, Ismi
    Hamdani, Musyarrafah
    Handayani, Meliana
    Padauleng, Andi W.
    Shabir, Achmad M.
    Hasyim, Hadijah
    Wadi, Ahmad
    Maidin, Alimin
    Sarkar, Alexandria
    West, Heidi S.
    Meng, Can
    Shibata, Tomoyuki
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2021, 52 (01) : 11 - 22
  • [38] New Approaches to Postoperative Radiotherapy for Cancer of the Head and Neck
    Prellop, Perri
    Ove, Roger
    CURRENT CANCER THERAPY REVIEWS, 2005, 1 (01) : 63 - 70
  • [39] Assessment of adjuvant therapy in resected head and neck cancer with high-risk features
    Ajmani, Gaurav S.
    Nocon, Cheryl C.
    Wang, Chi-Hsiung
    Bhayani, Mihir K.
    ORAL ONCOLOGY, 2017, 74 : 15 - 20
  • [40] Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer
    Clark, Joseph I.
    Eisner, Robert M.
    Hofmeister, Craig
    Norton, John
    Thomas, Sachdev
    Choudhury, Abdul
    Petruzzelli, Guy
    Lathers, Deanne
    Young, M. Rita I.
    Lau, Ann
    Emami, Bahman
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (04): : 396 - 400